Cathay Bloomberg Barclays US 20+ Treasury -1x ETF (00689R)
TWSE TWSE Primary Summary
00689R Chart
Cathay Bloomberg Barclays US 20+ Treasury -1x ETF (00689R) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cathay Bloomberg Barclays US 20+ Treasury -1x ETF ever had a stock split?
Cathay Bloomberg Barclays US 20+ Treasury -1x ETF Profile
| TWSE Exchange | France Country |
Overview
MaaT Pharma SA is a pioneering clinical-stage company focused on the innovative field of microbiome biotherapies, particularly for the treatment of solid cancer tumors. Since its incorporation in 2014, and with headquarters in Lyon, France, MaaT Pharma has embarked on the mission to leverage the therapeutic potential of the human microbiome to develop groundbreaking treatments for serious and life-threatening diseases. The company's dedication to research and development in microbiome science represents a cutting-edge approach to oncology and transplantation medicine, aiming to improve patient outcomes through microbiota-based interventions.
Products and Services
- MaaT013
- MaaT033
- MaaT03X
This biotherapy product has successfully completed phase 2 clinical trials and is designed primarily for the treatment of acute graft versus host diseases (GvHD), a severe complication following allogeneic stem cell transplantation. MaaT013 represents a significant advancement in managing GvHD, offering hope to patients with this challenging condition. Additionally, MaaT013 is undergoing preclinical trials for the treatment of melanoma, exploring its potential to impact solid cancer treatment through immunomodulation.
MaaT033 is currently in phase 1b clinical trials, targeting the improvement of survival rates in patients with acute myeloid leukemia (AML) or other liquid tumors who are undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The development of MaaT033 underscores MaaT Pharma’s commitment to extending the benefits of microbiome biotherapies beyond solid tumors to also include hematologic malignancies, potentially transforming the therapeutic landscape for patients facing these aggressive cancers.
A forward-looking product in the company's pipeline, MaaT03X is designed for the treatment of solid tumors. Through ongoing research and development efforts, MaaT Pharma aims to validate the efficacy and safety of MaaT03X, with the ultimate goal of providing a new therapeutic option for patients battling various forms of solid cancer. By expanding its pipeline to include solutions like MaaT03X, MaaT Pharma SA illustrates its comprehensive approach to leveraging microbiome science for cancer treatment.
